| Experience with sorafenib and adverse event management. | |
| | |
MedLine Citation:
|
PMID: 20399677 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Sorafenib was the first multikinase inhibitor to be approved for use in renal cell cancer (RCC) in the US (2005) and in Europe (2006). In the Treatment Approaches in Renal Cell Cancer Global Evaluation Trial (TARGET), sorafenib showed a significant progression-free survival advantage over placebo in patients with advanced RCC. Incidence rates of adverse events were significantly higher with sorafenib than with placebo. Management of adverse events is an essential component of care to prevent negative impact on patient quality of life and dose modification of sorafenib therapy. This report, based on an expert panel discussion held in February 2009, presents recommendations for the management of skin rash, hand-foot skin reaction, diarrhea, and hypertension, and strategies to help lessen the frequency and severity of these events. In addition, general recommendations for dose modifications are discussed. The goal of these management recommendations is to optimize sorafenib therapy for advanced RCC. |
| | |
Authors:
|
Joaquim Bellmunt; Timothy Eisen; Mayer Fishman; David Quinn |
Related Documents
:
|
17016297 - Avoiding hypothermia in the trauma patient. 15597747 - Music, musicians, and the brain: an exploration of musical genius. the 2004 presidentia... 10652837 - Bronchoscopy in small animal medicine: indications, instrumentation, and techniques. 15463317 - Use of benzimidazole chemotherapy in human helminthiases: indications and efficacy. 9371077 - Ignore growing patient interest in alternative medicine at your peril, mds warned. 16437747 - Inhibitory effects of anti-sars traditional chinese medicines on the uv irradiation of ... |
Publication Detail:
|
Type: Journal Article Date: 2010-04-18 |
Journal Detail:
|
Title: Critical reviews in oncology/hematology Volume: 78 ISSN: 1879-0461 ISO Abbreviation: Crit. Rev. Oncol. Hematol. Publication Date: 2011 Apr |
Date Detail:
|
Created Date: 2011-03-11 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8916049 Medline TA: Crit Rev Oncol Hematol Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 24-32 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved. |
Affiliation:
|
Solid Tumor Oncology Section (GU & GI), Medical Oncology Service, University Hospital del Mar-IMIM, Paseo Maritimo 25-29, Barcelona, Spain. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Importance of cerebral artery risk evaluation before off-pump coronary artery bypass grafting to avo...
Next Document: Guidelines, minimal requirements and standard of cancer care around the Mediterranean Area: Report f...